Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 9/20 | 0.44 |
| ▸ | NLN | Q9BYT8 | 2/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.39 |
| ▸ | SCN1A | P35498 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.39 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.39 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15105893 | 0.92 | SCN10A (0.39) | SCN10ANLNSCN5A | |
| SCHEMBL1315025 | 0.90 | NLN (0.46) | SCN10ANLNSCN5ASCN1AKCNH2 | |
| SCHEMBL19414850 | 0.90 | NLN (0.46) | SCN10ANLNSCN5ASCN1AKCNH2 | |
| SCHEMBL15105760 | 0.89 | HPGDS (0.42) | SCN10ANLN | |
| SCHEMBL20054101 | 0.89 | SCN10A (0.40) | SCN10ANLNSCN5ASCN1AKCNH2 | |
| SCHEMBL15113143 | 0.89 | SCN10A (0.40) | SCN10ANLNSCN5ASCN1AKCNH2 | |
| SCHEMBL18482470 | 0.89 | SCN10A (0.41) | SCN10ANLNSCN5A | |
| SCHEMBL19388462 | 0.85 | SCN10A (0.37) | SCN10ANLNSCN5ASCN1AKCNH2 | |
| SCHEMBL19388645 | 0.85 | SCN10A (0.40) | SCN10ANLNSCN5ASCN1AKCNH2 | |
| SCHEMBL15114359 | 0.85 | SCN10A (0.40) | SCN10ANLNSCN5ASCN1AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10617675-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-04-14 | — | — | US | disclosed |
| US-20180221342-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-08-09 | — | — | US | disclosed |
| US-9770439-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-26 | — | — | US | disclosed |
| WO-2017023631-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-02-09 | — | — | WO | disclosed |
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-06-09 | — | — | US | disclosed |
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-06-09 | — | — | US | disclosed |
| US-20150297568-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-10-22 | — | — | US | disclosed |
| US-20150023913-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2015-01-22 | — | — | US | disclosed |
| US-20150023913-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2015-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10617675-B2 | Hepatitis C virus inhibitors | HAVCR2, MAVS, EIF2AK2 | SCN10A 4191/4885NLN 4268/4885SCN5A 3899/4885 |
| US-20150023913-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | SCN10A 4191/4885NLN 4268/4885SCN5A 3899/4885 |
| US-20150297568-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | SCN10A 4191/4885NLN 4268/4885SCN5A 3899/4885 |
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | SCN10A 4318/4885NLN 4123/4885SCN5A 4146/4885 |
| US-20180221342-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, MAVS, EIF2AK2 | SCN10A 4191/4885NLN 4268/4885SCN5A 3899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.